Evaluation of DILI Predictive Hypotheses in Early Drug Development

Chemical Research in Toxicology

Volumn 30, Issue 4, 2017, Pages 1017-1029

  Chan, Rosa ^a   Benet, Leslie Z ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ALGORITHM; ARTICLE; CLASSIFICATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DISPOSITION; DRUG LABELING; DRUG SOLUBILITY; FOOD AND DRUG ADMINISTRATION; HYPOTHESIS; NONHUMAN; PREDICTIVE VALUE; TOXIC HEPATITIS; HUMAN; PATHOLOGY; PHARMACEUTICS; PRECLINICAL STUDY; SEVERITY OF ILLNESS INDEX; THEORETICAL MODEL;

BIOPHARMACEUTICS; CHEMICAL AND DRUG INDUCED LIVER INJURY; DRUG EVALUATION, PRECLINICAL; DRUG LABELING; HUMANS; MODELS, THEORETICAL; SEVERITY OF ILLNESS INDEX;

EID: 85018490194     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/acs.chemrestox.7b00025     Document Type: Article

References (33)

1. Lammert, C., Bjornsson, E., Niklasson, A., and Chalasani, N. ( 2010 ) Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events Hepatology 51, 615-620 10.1002/hep.23317
2. Lammert, C., Einarsson, S., Saha, C., Niklasson, A., Bjornsson, E., and Chalasani, N. ( 2008 ) Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals Hepatology 47, 2003-2009 10.1002/hep.22272
3. Lewis, J. H. ( 2014 ) Drug-induced liver injury, dosage, and drug disposition: is idiosyncrasy really unpredictable? Clin. Gastroenterol. Hepatol. 12, 1556-1561 10.1016/j.cgh.2014.02.011
4. Chen, M., Suzuki, A., Borlak, J., Andrade, R. J., and Isabel Lucena, M. ( 2015 ) Drug-induced liver injury: interactions between drug properties and host factors J. Hepatol. 63, 503-514 10.1016/j.jhep.2015.04.016
5. Thompson, R. A., Isin, E. M., Ogese, M. O., Mettetal, J. T., and Williams, D. P. ( 2016 ) Reactive Metabolites: Current and Emerging Risk and Hazard Assessments Chem. Res. Toxicol. 29, 505-533 10.1021/acs.chemrestox.5b00410
6. Srivastava, A., Maggs, J. L., Antoine, D. J., Williams, D. P., Smith, D. A., and Park, B. K. ( 2010 ) Role of reactive metabolites in drug-induced hepatotoxicity Handb. Exp. Pharmacol. 196, 165-194 10.1007/978-3-642-00663-0_7
7. Knowles, S. R., Uetrecht, J., and Shear, N. H. ( 2000 ) Idiosyncratic drug reactions: the reactive metabolite syndromes Lancet 356, 1587-1591 10.1016/S0140-6736(00)03137-8
8. Jaeschke, H., Gores, G. J., Cederbaum, A. I., Hinson, J. A., Pessayre, D., and Lemasters, J. J. ( 2002 ) Mechanisms of hepatotoxicity Toxicol. Sci. 65, 166-176 10.1093/toxsci/65.2.166
9. Chen, M., Borlak, J., and Tong, W. ( 2013 ) High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury Hepatology 58, 388-396 10.1002/hep.26208
10. Wu, C.-Y. and Benet, L. Z. ( 2005 ) Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a Biopharmaceutics Drug Disposition Classification System Pharm. Res. 22, 11-23 10.1007/s11095-004-9004-4
11. Benet, L. Z. ( 2010 ) Predicting drug disposition via application of a biopharmaceutics drug disposition classification system Basic Clin. Pharmacol. Toxicol. 106, 162-167 10.1111/j.1742-7843.2009.00498.x
12. Chan, R., Wei, C., Chen, Y., and Benet, L. Z. ( 2016 ) Use of the biopharmaceutics drug disposition classification system (BDDCS) to help predict the occurrence of idiosyncratic cutaneous adverse drug reactions associated with antiepileptic drug usage AAPS J. 18, 757-766 10.1208/s12248-016-9898-x
13. Chen, M., Borlak, J., and Tong, W. ( 2016 ) A model to predict severity of drug-induced liver injury in humans Hepatology 64, 931-940 10.1002/hep.28678
14. Schadt, S., Simon, S., Kustermann, S., Boess, F., McGinnis, C., Brink, A., Lieven, R., Fowler, S., Youdim, K., Ullah, M., Marschmann, M., Zihlmann, C., Siegrist, Y. M., Cascais, A. C., Di Lenarda, E., Durr, E., Schaub, N., Ang, X., Starke, V., Singer, T., Alvarez-Sanchez, R., Roth, A. B., Schuler, F., and Funk, C. ( 2015 ) Minimizing DILI risk in drug discovery-A screening tool for drug candidates Toxicol. In Vitro 30, 429-437 10.1016/j.tiv.2015.09.019
15. Pedersen, J. M., Matsson, P., Bergström, C. a S., Hoogstraate, J., Norén, A., LeCluyse, E. L., and Artursson, P. ( 2013 ) Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11) Toxicol. Sci. 136, 328-343 10.1093/toxsci/kft197
16. Zhang, J., Doshi, U., Suzuki, A., Chang, C. W., Borlak, J., Li, A. P., and Tong, W. ( 2016 ) Evaluation of multiple mechanism-based toxicity endpoints in primary cultured human hepatocytes for the identification of drugs with clinical hepatotoxicity: Results from 152 marketed drugs with known liver injury profiles Chem.-Biol. Interact. 255, 3-11 10.1016/j.cbi.2015.11.008
17. Trontell, A. E. ( 2001 ) How the US food and drug administration defines and detects adverse drug events Curr. Ther. Res. 62, 641-649 10.1016/S0011-393X(01)80070-9
18. Chen, M., Vijay, V., Shi, Q., Liu, Z., Fang, H., and Tong, W. ( 2011 ) FDA-approved drug labeling for the study of drug-induced liver injury Drug Discovery Today 16, 697-703 10.1016/j.drudis.2011.05.007
19. United States Food and Drug Administration ( 2011 ) Guidance for Industry Warning and Precautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drug and Biological Products-Content and Format, United States Food and Drug Administration, Silver Spring, MD.
20. United States Food and Drug Administration ( 2006 ) Guidance for Industry Adverse Reactions Section of Labeling for Human Prescription Drug and Biological Products: Content and Format, United States Food and Drug Administration, Silver Spring, MD.
21. United States Food and Drug Administration ( 2013 ) Guidance for Industry Labeling for Human Prescription Drug and Biological Products: Implementing the New Content and Format Requirements, United States Food and Drug Administration, Silver Spring, MD.
22. Benet, L. Z., Broccatelli, F., and Oprea, T. I. ( 2011 ) BDDCS applied to over 900 drugs AAPS J. 13, 519-547 10.1208/s12248-011-9290-9
23. Hosey, C. M., Chan, R., and Benet, L. Z. ( 2016 ) BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs AAPS J. 18, 251-260 10.1208/s12248-015-9845-2
24. Hosey, C. M. and Benet, L. Z. ( 2015 ) Predicting the extent of metabolism using in vitro permeability rate measurements and in silico permeability rate predictions Mol. Pharmaceutics 12, 1456-1466 10.1021/mp500783g
25. Dave, R. A. and Morris, M. E. ( 2016 ) Novel high/low solubility classification methods for new molecular entities Int. J. Pharm. 511, 111-126 10.1016/j.ijpharm.2016.06.060
26. R Core Team ( 2014 ) R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing, Vienna, Austria.
27. Wickham, H. ( 2009 ) ggplot2: Elegant Graphics for Data Analysis, Springer-Verlag, New York.
28. Aleo, M. D., Luo, Y., Swiss, R., Bonin, P. D., Potter, D. M., and Will, Y. ( 2014 ) Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump Hepatology 60, 1015-1022 10.1002/hep.27206
29. Russmann, S., Kullak-Ublick, G. a, and Grattagliano, I. ( 2009 ) Current concepts of mechanisms in drug-induced hepatotoxicity Curr. Med. Chem. 16, 3041-3053 10.2174/092986709788803097
30. Uetrecht, J. and Dan, L. ( 2007 ) Idiosyncratic drug reactions: Current understanding Annu. Rev. Pharmacol. Toxicol. 47, 513-539 10.1146/annurev.pharmtox.47.120505.105150
31. Broccatelli, F., Cruciani, G., Benet, L. Z., and Oprea, T. I. ( 2012 ) BDDCS class prediction for new molecular entities Mol. Pharmaceutics 9, 570-580 10.1021/mp2004302
32. Vuppalanchi, R., Gotur, R., Reddy, K. R., Fontana, R. J., Ghabril, M., Kosinski, A. S., Gu, J., Serrano, J., and Chalasani, N. ( 2014 ) Relationship between characteristics of medications and drug-induced liver disease phenotype and outcome Clin. Gastroenterol. Hepatol. 12, 1550-1555 10.1016/j.cgh.2013.12.016
33. Benet, L. Z. ( 2013 ) The role of BCS (Biopharmaceutics Classification System) and BDDCS (Biopharmaceutics Drug Disposition Classification System) in drug development J. Pharm. Sci. 102, 34-42 10.1002/jps.23359